NDA 018086 · Bausch and Lomb INC
Timoptic
Timolol Maleate · Ophthalmic
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Aug 17, 1978
Approved uses
1
Original approval plus efficacy supplements
Registered trials
306
98 Phase 3, 14 recruiting
FAERS reports
9,481
4,819 serious, 575 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 4, 2025.
INDICATIONS AND USAGE Timolol Maleate Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Mechanism: Mechanism of Action Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function. Beta-adrenergic...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 17, 1978 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- TIMOPTIC · TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT1
- TIMOPTIC · TIMOLOL MALEATE EQ 0.25% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT1
Clinical trials
Interventional ClinicalTrials.gov studies with "Timolol" as an intervention, any sponsor and status, largest first.
- Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02207621 · 756 participants · Start Jul 2014 · Primary completion Mar 2016
Drug: AR-13324 Ophthalmic Solution 0.02%; Timolol maleate Ophthalmic Solution 0.5% BID and 1 more · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Bedminster, New Jersey
AllerganAbbVie (ABBV)
NCT02571712 · 750 participants · Start Nov 10, 2015 · Primary completion Jun 21, 2018
Drug: bimatoprost 0.03% plus timolol 0.5% · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 15 sites in all
- Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02558374 · 708 participants · Start Sep 2015 · Primary completion Dec 2016
Drug: AR-13324 Ophthalmic Solution 0.02%; Timolol Maleate Ophthalmic Solution 0.5% BID · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01026831 · 643 participants · Start Jan 6, 2010 · Primary completion Sep 17, 2010
Drug: Preservative-Free Tafluprost; Comparator: timolol · For: Open-angle Glaucoma; Ocular Hypertension
- Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension PatientsPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00651612 · 604 participants · Start Nov 2005 · Primary completion Jan 2007
Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution; Concurrent brimonidine 0.2% and 0.5% timolol · For: Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against MonotherapiesPivotal-lookingCompleted
Santen OyIndustry
NCT01292460 · 600 participants (planned) · Start Feb 2011 · Primary completion Sep 2012
Drug: Timolol/ FDC/ Placebo/ Tafluprost · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Kuopio, Finland; Oulu, Finland
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02247804 · 594 participants · Start Dec 15, 2014 · Primary completion Feb 19, 2018
Drug: Bimatoprost SR; Active Comparator: Timolol 0.5% and 1 more · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Phoenix, Arizona; Glendale, California; Irvine, California · 106 sites in all
- Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%Pivotal-lookingCompleted
Glaukos CorporationIndustry
NCT03519386 · 590 participants · Start Jul 26, 2018 · Primary completion Apr 5, 2022
Drug: Sham surgery + active-comparator eye drops · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Sioux Falls, South Dakota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure1,009
- drug ineffective668
- eye pain503
- fatigue502
- eye irritation432
- dizziness363
- diarrhoea341
- nausea337
- vision blurred316
- dyspnoea309
- headache302
- off label use298
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 250 |
| 2005 | 287 |
| 2006 | 250 |
| 2007 | 239 |
| 2008 | 218 |
| 2009 | 213 |
| 2010 | 290 |
| 2011 | 278 |
| 2012 | 385 |
| 2013 | 166 |
| 2014 | 205 |
| 2015 | 337 |
| 2016 | 384 |
| 2017 | 423 |
| 2018 | 435 |
| 2019 | 505 |
| 2020 | 1,537 |
| 2021 | 474 |
| 2022 | 500 |
| 2023 | 568 |
| 2024 | 560 |
| 2025 | 600 |
| 2026 | 376 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Bausch and Lomb INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.